Replimune is preparing for a third attempt to gain FDA approval for its drug, a significant milestone for the company as it navigates regulatory challenges.
In related news, Pfizer has successfully secured a deal in China, indicating its continued expansion and strategic partnerships in international markets.
These updates reflect the dynamic nature of the pharmaceutical industry, where companies are constantly seeking to innovate and adapt to regulatory landscapes.